These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1903911)

  • 21. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa.
    Masuda N; Ohya S
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1847-51. PubMed ID: 1416876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy.
    Horii T; Muramatsu H; Morita M; Maekawa M
    Microb Drug Resist; 2003; 9(2):223-9. PubMed ID: 12820809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predominance of carbapenem-resistant Pseudomonas aeruginosa isolates carrying blaIMP and blaVIM metallo-β-lactamases in a major hospital in Costa Rica.
    Toval F; Guzmán-Marte A; Madriz V; Somogyi T; Rodríguez C; García F
    J Med Microbiol; 2015 Jan; 64(Pt 1):37-43. PubMed ID: 25355933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Assessment of 2 automated microdilution techniques compared to an agar dilution method in determining sensitivity to fosfomycin in strains of carbapenem-resistant Pseudomonas aeruginosa].
    Gil-Romero Y; Regodón-Domínguez M; Wilhelmi de Cal I; López-Fabal F; Gómez-Garcés JL
    Enferm Infecc Microbiol Clin; 2016; 34(7):406-8. PubMed ID: 26620604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
    Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
    J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wide variability in Pseudomonas aeruginosa aminoglycoside results among seven susceptibility testing procedures.
    Staneck JL; Glenn S; DiPersio JR; Leist PA
    J Clin Microbiol; 1989 Oct; 27(10):2277-85. PubMed ID: 2511223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Prevalence of Metallo-β-Lactamases and Efflux-Mediated Mechanisms in Carbapenem Nonsusceptible Nosocomial Pseudomonas aeruginosa Isolated in Moscow in 2012-2015].
    Vestn Ross Akad Med Nauk; 2015; (6):679-83. PubMed ID: 27093795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Implementation of a Hospital-wide Practice for the Selective Use of Carbapenems Based on the Monitoring of Susceptibility of Pseudomonas aeruginosa Isolates.
    Ohshima T; Asai S; Miyazawa M; Yamamoto Y; Hisada A; Kumazawa C; Hashimoto M; Fukawa K; Iwashita H; Umezawa K; Yamada S; Yamamoto Y; Miyachi H
    Tokai J Exp Clin Med; 2017 Dec; 42(4):176-181. PubMed ID: 29228415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.
    Castanheira M; Deshpande LM; Costello A; Davies TA; Jones RN
    J Antimicrob Chemother; 2014 Jul; 69(7):1804-14. PubMed ID: 24603963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
    Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
    Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
    J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigating of four main carbapenem-resistance mechanisms in high-level carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
    Rostami S; Farajzadeh Sheikh A; Shoja S; Farahani A; Tabatabaiefar MA; Jolodar A; Sheikhi R
    J Chin Med Assoc; 2018 Feb; 81(2):127-132. PubMed ID: 29033110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of different lots of Mueller-Hinton agar on the interpretation of the gentamicin susceptibility of Pseudomonas aeruginosa.
    Pollock HM; Minshew BH; Kenny MA; Schoenknecht FD
    Antimicrob Agents Chemother; 1978 Sep; 14(3):360-7. PubMed ID: 101130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
    Margaret BS; Drusano GL; Standiford HC
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():161-7. PubMed ID: 2509413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
    Poirel L; Ortiz De La Rosa JM; Kieffer N; Dubois V; Jayol A; Nordmann P
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative activity of beta-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA beta-lactamases.
    Bert F; Branger C; Lambert-Zechovsky N
    Chemotherapy; 2004 Apr; 50(1):31-4. PubMed ID: 15084803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams.
    Wu PJ; Livermore DM
    J Antimicrob Chemother; 1990 Jun; 25(6):891-902. PubMed ID: 2115037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.
    Zincke D; Balasubramanian D; Silver LL; Mathee K
    Antimicrob Agents Chemother; 2016 Feb; 60(2):936-45. PubMed ID: 26621621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a Modified Carbapenem Inactivation Method for Detection of Carbapenemases in Pseudomonas aeruginosa.
    Lisboa LF; Turnbull L; Boyd DA; Mulvey MR; Dingle TC
    J Clin Microbiol; 2018 Jan; 56(1):. PubMed ID: 29070655
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.